ENGAGE-1 (NCT02528357) is a phase I dose-escalation study evaluating the safety and effectiveness of GSK998 (humanized IgG1 mAb that targets and stimulates OX40 on T cells) alone and in combination with pembrolizumab in patients with previously treated advanced solid tumors, including NSCLC. This evidence concerns the gene TNFRSF4 and non-small cell lung carcinoma.